This database contains 57 studies, archived under the term: "donepezil"
Click here to filter this large number of results.
Errorless practice as a possible adjuvant to donepezil in Alzheimer’s disease
Rothi, Leslie J. Gonzalez,
Fuller, Renee,
Leon, Susan A.,
Kendall, Diane,
Moore, Anna,
Wu, Samuel S.,
Crosson, Bruce,
Heilman, Kenneth M.,
Nadeau, Stephen E.
Six individuals with probable Alzheimer’s disease (AD) participated in a phase 1 study employing a repeated measures, parallel baseline design testing the hypothesis that error-free experience during word production practice combined with an acetyl cholinesterase inhibitor would improve confrontation naming ability. While acetyl cholinesterase inhibitors are safe and delay cognition decline associated with AD, improvement […]
Long-term safety and efficacy of donepezil in patients with severe Alzheimer’s disease: results from a 52-week, open-label, multicenter, extension study in Japan
Homma, Akira,
Imai, Yukimichi,
Tago, Hisao,
Asada, Takashi,
Shigeta, Masahiro,
Iwamoto, Toshihiko,
Takita, Masashi,
Arimoto, Itaru,
Koma, Hiroshi,
Takase, Takao,
Ohbayashi, Toshio
Background/aims: A 6-month, randomized, double-blind, placebo-controlled study was extended to evaluate long-term safety and efficacy of donepezil in community-dwelling Japanese patients with severe Alzheimer’s disease (AD).; Methods: 189 patients were enrolled from the double-blind study into a 52-week, open-label extension study. After a 2- to 8-week washout, donepezil was escalated within 6 weeks to 10 […]
Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design
Pelton, Gregory H.,
Andrews, Howard,
Roose, Steven P.,
Marcus, Sue M.,
D'Antonio, Kristina,
Husn, Hala,
Petrella, Jeffrey R.,
Zannas, Anthony S.,
Doraiswamy, P. Murali,
Devanand, D. P.
Treatment strategies for patients with depression and cognitive impairment (DEP-CI), who are at high risk to develop a clinical diagnosis of dementia, are not established. This issue is addressed in the donepezil treatment of cognitive impairment and depression (DOTCODE) pilot clinical trial. The DOTCODE study is the first long-term treatment trial that assesses differences in […]
Concentration of donepezil to the cognitive response in Alzheimer disease
Yang, Yuan-Han,
Chen, Chun-Hung,
Chou, Mei-Chuan,
Li, Chien-Hsun,
Liu, Ching-Kuan,
Chen, Su-Hwei
Background: Donepezil has been approved, and higher dosages are recommended for the treatment of Alzheimer disease (AD). However, a few studies have reported different cognitive responses in patients with AD treated with donepezil without measuring the concentration.; Methods: We evaluated the relationships between the therapeutic responses and plasma concentrations of donepezil in various cognitive domains […]
The long-term efficacy and tolerability of donepezil in patients with vascular dementia
Wilkinson, David,
Róman, Gustavo,
Salloway, Stephen,
Hecker, Jane,
Boundy, Karyn,
Kumar, Dinesh,
Posner, Holly,
Schindler, Rachel
Objective: To determine the long-term tolerability and efficacy of donepezil in patients with vascular dementia (VaD).; Methods: International, multicentre, open-label, 30-week extension study of two 24-week, randomised, double-blind, placebo-controlled studies. Participants were ambulatory adults (59% female; mean age, 74.7 +/- 0.3) with a diagnosis of possible or probable VaD and without a diagnosis of Alzheimer’s […]
Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep
Many patients with Alzheimer’s disease experience sleep disturbances, and donepezil is usually prescribed for night-time administration. However, increased acetylcholine is associated with cortical arousal. We evaluated whether subjective sleep quality differed according to the timing of medication administration. Ninety-two patients with mild to moderate Alzheimer’s disease who had taken donepezil at night (n=54) or galantamine […]
Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer’s disease
Solé-Padullés, Cristina,
Bartrés-Faz, David,
Lladó, Albert,
Bosch, Beatriz,
Peña-Gómez, Cleofé,
Castellví, Magdalena,
Rami, Lorena,
Bargalló, Nuria,
Sánchez-Valle, Raquel,
Molinuevo, José Luis
Previous studies with functional magnetic resonance imaging (fMRI) demonstrated a differential brain activity and connectivity after treatment with donepezil in Alzheimer’s disease (AD) when compared to healthy elders. Importantly however, there are no available studies where the placebo or control group included comparable AD patients relative to the treated groups. Fifteen patients recently diagnosed of […]
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
Sabbagh, Marwan,
Cummings, Jeffrey,
Christensen, Daniel,
Doody, Rachelle,
Farlow, Martin,
Liu, Liang,
Mackell, Joan,
Fain, Randi
Background: Treatment of Alzheimer’s disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated with either donepezil 23 mg/d or 10 mg/d and to identify factors potentially influencing response.; Methods: […]